retatrutide pharmacokinetics Intranasal retatrutide: nasal spray delivery, bioavailability, all you need to know Triple hormone receptor agonist retatrutide

Upgrading to Shotsy+ unlocks additional features like Apple Health integration, advanced charts, and PDF export for $9.99/month or $59.99/year

For a soothing option, try soothing chicken ginger broth

Key Takeaways Retatrutide is being studied as a triple agonist that targets GIP, GLP-1, and glucagon receptors

Recent studies showed that patients taking the drug lost 15% to 20% of their body weight over 68 weeks, Insider's Gabby Landsverk previously reported

These may include: Nausea, vomiting or diarrhoea (most common early on) Constipation Fatigue Mild increases in heart rate (similar to changes seen with GLP-1 medicines) Side effects were more frequent at higher doses (8 mg and 12 mg), but still rated mild to moderate overall

This can include the following activities: Analyzing your population data